Taeko Matsuura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Taeko Matsuura has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Kikuo Umegaki
Faculty of Engineering Hokkaido University Sapporo Hokkaido Japan
12 shared publicationsHiroki Shirato
Department of Proton Beam Therapy Faculty of Medicine Hokkaido University Sapporo Hokkaido 0608648 Japan
7 shared publicationsNaoki Miyamoto
Division of Quantum Science and Engineering Faculty of Engineering Hokkaido University Sapporo Hokkaido 0608628 Japan
7 shared publicationsSeishin Takao
Proton Beam Therapy Center Hokkaido University Hospital Sapporo Hokkaido 0608638 Japan
7 shared publicationsShinichi Shimizu
Proton Beam Therapy Center Hokkaido University Hospital Sapporo Hokkaido 0608638 Japan
6 shared publicationsYusuke Fujii
Graduate School of Engineering Hokkaido University Sapporo Hokkaido Japan
5 shared publications
Latest Publications
- 23 January 2023
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 96 (1144) , 20220720
Study of hepatic toxicity in small liver tumors after photon or proton therapy based on factors predicting the benefits of proton
Objectives: In a previous study of hepatic toxicity, the following three factors were identified to predict the benefits of proton beam therapy (PBT) for hepatocellular carcinomas (HCCs) with a maximum diameter of ≤5 cm and Child-pugh grade A (CP-A): number of tumors (1 vs ≥2), the location of tumors (hepatic hilum or others), and the sum of the diameters of lesions. The aim of this study is to analyze the association between these three factors and hepatic toxicity. Methods: We retrospectively reviewed patients of CP-A treated with PBT or photon stereotactic body radiotherapy (X-ray radiotherapy, XRT) for HCC ≤5 cm. For normal liver dose, the V5, V10, V20 (volumes receiving 5, 10, and 20 Gy at least), and the mean dose was evaluated. The albumin-bilirubin (ALBI) and CP score changes from the baseline were evaluated at 3 and 6 months after treatment. Results: In 89 patients (XRT: 48, PBT: 41), those with two or three (2–3) predictive factors were higher normal liver doses than with zero or one (0–1) factor. In the PBT group, the ALBI score worsened more in patients with 2–3 factors than those with 0–1 factor, at 3 months (median: 0.26 vs 0.02, p = 0.032) and at 6 months (median: 0.35 vs 0.10, p = 0.009). The ALBI score change in the XRT group and CP score change in either modality were not significantly different in the number of predictive factors. Conclusion: The predictive factor numbers predicted the ALBI score change in PBT but not in XRT. Advances in knowledge: This study suggest that the number of predictive factors previously identified (0–1 vs 2–3) were significantly associated with dosimetric parameters of the normal liver in both modalities. In the proton group, the number of predictive factors was associated with a worsening ALBI score at 3 and 6 months, but these associations were not found in the photon SBRT group.
- 23 January 2023
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 96 (1144) , 20220720
Study of hepatic toxicity in small liver tumors after photon or proton therapy based on factors predicting the benefits of proton
Objectives: In a previous study of hepatic toxicity, the following three factors were identified to predict the benefits of proton beam therapy (PBT) for hepatocellular carcinomas (HCCs) with a maximum diameter of ≤5 cm and Child-pugh grade A (CP-A): number of tumors (1 vs ≥2), the location of tumors (hepatic hilum or others), and the sum of the diameters of lesions. The aim of this study is to analyze the association between these three factors and hepatic toxicity. Methods: We retrospectively reviewed patients of CP-A treated with PBT or photon stereotactic body radiotherapy (X-ray radiotherapy, XRT) for HCC ≤5 cm. For normal liver dose, the V5, V10, V20 (volumes receiving 5, 10, and 20 Gy at least), and the mean dose was evaluated. The albumin-bilirubin (ALBI) and CP score changes from the baseline were evaluated at 3 and 6 months after treatment. Results: In 89 patients (XRT: 48, PBT: 41), those with two or three (2–3) predictive factors were higher normal liver doses than with zero or one (0–1) factor. In the PBT group, the ALBI score worsened more in patients with 2–3 factors than those with 0–1 factor, at 3 months (median: 0.26 vs 0.02, p = 0.032) and at 6 months (median: 0.35 vs 0.10, p = 0.009). The ALBI score change in the XRT group and CP score change in either modality were not significantly different in the number of predictive factors. Conclusion: The predictive factor numbers predicted the ALBI score change in PBT but not in XRT. Advances in knowledge: This study suggest that the number of predictive factors previously identified (0–1 vs 2–3) were significantly associated with dosimetric parameters of the normal liver in both modalities. In the proton group, the number of predictive factors was associated with a worsening ALBI score at 3 and 6 months, but these associations were not found in the photon SBRT group.
- Open Access
A Consistent Protocol Reveals a Large Heterogeneity in the Biological Effectiveness of Proton and Carbon-Ion Beams for Various Sarcoma and Normal-Tissue-Derived Cell Lines
This study investigated variations in the relative biological effectiveness (RBE) values among various sarcoma and normal-tissue-derived cell lines (normal cell line) in proton beam and carbon-ion irradiations. We used a consistent protocol that specified the timing of irradiation after plating cells and detailed the colony formation assay. We examined the cell type dependence of RBE for proton beam and carbon-ion irradiations using four human sarcoma cell lines (MG63 osteosarcoma, HT1080 fibrosarcoma, SW872 liposarcoma, and SW1353 chondrosarcoma) and three normal cell lines (HDF human dermal fibroblast, hTERT-HME1 mammary gland, and NuLi-1 bronchus epithelium). The cells were irradiated with gamma rays, proton beams at the center of the spread-out Bragg peak, or carbon-ion beams at 54.4 keV/μm linear energy transfer. In all sarcoma and normal cell lines, the average RBE values in proton beam and carbon-ion irradiations were 1.08 ± 0.11 and 2.08 ± 0.36, which were consistent with the values of 1.1 and 2.13 used in current treatment planning systems, respectively. Up to 34% difference in the RBE of the proton beam was observed between MG63 and HT1080. Similarly, a 32% difference in the RBE of the carbon-ion beam was observed between SW872 and the other sarcoma cell lines. In proton beam irradiation, normal cell lines had less variation in RBE values (within 10%), whereas in carbon-ion irradiation, RBE values differed by up to 48% between hTERT-HME1 and NuLi-1. Our results suggest that specific dose evaluations for tumor and normal tissues are necessary for treatment planning in both proton and carbon-ion therapies.
Open AccessA Consistent Protocol Reveals a Large Heterogeneity in the Biological Effectiveness of Proton and Carbon-Ion Beams for Various Sarcoma and Normal-Tissue-Derived Cell Lines
This study investigated variations in the relative biological effectiveness (RBE) values among various sarcoma and normal-tissue-derived cell lines (normal cell line) in proton beam and carbon-ion irradiations. We used a consistent protocol that specified the timing of irradiation after plating cells and detailed the colony formation assay. We examined the cell type dependence of RBE for proton beam and carbon-ion irradiations using four human sarcoma cell lines (MG63 osteosarcoma, HT1080 fibrosarcoma, SW872 liposarcoma, and SW1353 chondrosarcoma) and three normal cell lines (HDF human dermal fibroblast, hTERT-HME1 mammary gland, and NuLi-1 bronchus epithelium). The cells were irradiated with gamma rays, proton beams at the center of the spread-out Bragg peak, or carbon-ion beams at 54.4 keV/μm linear energy transfer. In all sarcoma and normal cell lines, the average RBE values in proton beam and carbon-ion irradiations were 1.08 ± 0.11 and 2.08 ± 0.36, which were consistent with the values of 1.1 and 2.13 used in current treatment planning systems, respectively. Up to 34% difference in the RBE of the proton beam was observed between MG63 and HT1080. Similarly, a 32% difference in the RBE of the carbon-ion beam was observed between SW872 and the other sarcoma cell lines. In proton beam irradiation, normal cell lines had less variation in RBE values (within 10%), whereas in carbon-ion irradiation, RBE values differed by up to 48% between hTERT-HME1 and NuLi-1. Our results suggest that specific dose evaluations for tumor and normal tissues are necessary for treatment planning in both proton and carbon-ion therapies.
- 5 February 2022
- Published by Wiley in Medical Physics
- Vol. 49 (3) , 1839-1852
An initial systematic study of the linear energy transfer distributions of a proton beam under a transverse magnetic field
Purpose: To evaluate the biological effectiveness of magnetic resonance (MR)‐guided proton beam therapy, comprehensively characterizing the dose and dose‐averaged linear energy transfer (LETd) distributions under a magnetic field is necessary. Although detailed analysis has characterized curved beam paths and distorted dose distributions, the impact of a magnetic field on LETd should also be explored to determine the proton relative biological effectiveness (RBE). Hence, this initial study aims to present a basic analysis of LETd distributions in the presence of a magnetic field using Monte Carlo simulation (MCS).Methods: Geant4 MCS (version 10.1.p01) was performed to calculate the LETd distribution of proton beams. The incident beam energies were set to 70.2, 140.8, and 220 MeV, and both zero‐ and finite‐emittance pencil beams as well as scanned field were simulated. A transverse magnetic field of 0–3 T was applied within a water phantom placed at the isocenter, and the three‐dimensional dose and LETd distributions in the phantom were calculated. Then, the depth profiles of LETd along the curved trajectory and the lateral LETd profile at the Bragg peak (BP) depth were analyzed under changing energies and magnetic fields. In addition, for zero‐ and finite‐emittance beams, the correlation of the lateral asymmetries between the dose and LETd distributions were analyzed. Finally, spread‐out Bragg peak (SOBP) fields were simulated to assess the depth‐dependent asymmetry of the LETd distributions.Results: A transverse magnetic field distorted the lateral LETd distribution of a pencil beam at close to the BP, and the magnitude of the distortion at the BP increased for higher energy beams and larger magnetic fields. For a zero‐emittance beam, the differences in LETd between the left and right D20 positions were relatively large; the difference in LETd was 1.5 and 2.3 keV/μm at 140.8 and 220 MeV, respectively, at a magnetic field of 1.5 T. These asymmetries were pronounced at positions where the dose asymmetries were large. The size of the asymmetry was less substantial for a finite‐emittance beam and even less for a scanned field. However, a 1.5‐keV/μm difference still remained between the left and right D20 positions of a scanned field penumbra for a 220 MeV beam under the same magnetic field. For the SOBP field, it was found that the distal region of SOBP had the highest LETd distortions, followed by the central and proximal regions for the middle‐sized SOBP (5 × 5 × 5 cm3), whereas the degree of LETd distortion did not vary much with depth for the 10 × 10 × 10‐cm3 SOBP field.Conclusion: Our results indicate that not only the dose but also LETd distortions should be considered to accurately evaluate the biological effectiveness of MR‐guided proton beam therapy.
- 5 February 2022
- Published by Wiley in Medical Physics
- Vol. 49 (3) , 1839-1852
An initial systematic study of the linear energy transfer distributions of a proton beam under a transverse magnetic field
Purpose: To evaluate the biological effectiveness of magnetic resonance (MR)‐guided proton beam therapy, comprehensively characterizing the dose and dose‐averaged linear energy transfer (LETd) distributions under a magnetic field is necessary. Although detailed analysis has characterized curved beam paths and distorted dose distributions, the impact of a magnetic field on LETd should also be explored to determine the proton relative biological effectiveness (RBE). Hence, this initial study aims to present a basic analysis of LETd distributions in the presence of a magnetic field using Monte Carlo simulation (MCS).Methods: Geant4 MCS (version 10.1.p01) was performed to calculate the LETd distribution of proton beams. The incident beam energies were set to 70.2, 140.8, and 220 MeV, and both zero‐ and finite‐emittance pencil beams as well as scanned field were simulated. A transverse magnetic field of 0–3 T was applied within a water phantom placed at the isocenter, and the three‐dimensional dose and LETd distributions in the phantom were calculated. Then, the depth profiles of LETd along the curved trajectory and the lateral LETd profile at the Bragg peak (BP) depth were analyzed under changing energies and magnetic fields. In addition, for zero‐ and finite‐emittance beams, the correlation of the lateral asymmetries between the dose and LETd distributions were analyzed. Finally, spread‐out Bragg peak (SOBP) fields were simulated to assess the depth‐dependent asymmetry of the LETd distributions.Results: A transverse magnetic field distorted the lateral LETd distribution of a pencil beam at close to the BP, and the magnitude of the distortion at the BP increased for higher energy beams and larger magnetic fields. For a zero‐emittance beam, the differences in LETd between the left and right D20 positions were relatively large; the difference in LETd was 1.5 and 2.3 keV/μm at 140.8 and 220 MeV, respectively, at a magnetic field of 1.5 T. These asymmetries were pronounced at positions where the dose asymmetries were large. The size of the asymmetry was less substantial for a finite‐emittance beam and even less for a scanned field. However, a 1.5‐keV/μm difference still remained between the left and right D20 positions of a scanned field penumbra for a 220 MeV beam under the same magnetic field. For the SOBP field, it was found that the distal region of SOBP had the highest LETd distortions, followed by the central and proximal regions for the middle‐sized SOBP (5 × 5 × 5 cm3), whereas the degree of LETd distortion did not vary much with depth for the 10 × 10 × 10‐cm3 SOBP field.Conclusion: Our results indicate that not only the dose but also LETd distortions should be considered to accurately evaluate the biological effectiveness of MR‐guided proton beam therapy.
- 26 June 2021
- Published by Wiley in Medical Physics
- Vol. 48 (9) , 5490-5500
Technical Note: Range verification of pulsed proton beams from fixed‐field alternating gradient accelerator by means of time‐of‐flight measurement of ionoacoustic waves
Purpose: Ionoacoustics is one of the promising approaches to verify the beam range in proton therapy. However, the weakness of the wave signal remains a main hindrance to its application in clinics. Here we studied the potential use of a fixed‐field alternating gradient accelerator (FFA), one of the accelerator candidates for future proton therapy. For such end, magnitude of the pressure wave and range accuracy achieved by the short‐pulsed beam of FFA were assessed, using both simulation and experimental procedure.Methods: A 100 MeV proton beam from the FFA was applied on a water phantom, through the acrylic wall. The beam range measured by the Bragg peak (BP)‐ionization chamber (BPC) was 77.6 mm, while the maximum dose at BP was estimated to be 0.35 Gy/pulse. A hydrophone was placed 20 mm downstream of the BP, and signals were amplified and stored by a digital oscilloscope, averaged, and low‐pass filtered. Time‐of‐flight (TOF) and two relative TOF values were analyzed in order to determine the beam range. Furthermore, an acoustic wave transport simulation was conducted to estimate the amplitude of the pressure waves.Results: The range calculated when using two relative TOF was 78.16 ± 0.01 and 78.14 ± 0.01 mm, respectively, both values being coherent with the range measured by the BPC (the difference was 0.5‒0.6 mm). In contrast, utilizing the direct TOF resulted in a range error of 1.8 mm. Fivefold and 50‐fold averaging were required to suppress the range variation to below 1 mm for TOF and relative TOF measures, respectively. The simulation suggested the magnitude of pressure wave at the detector exceeded 7 Pascal.Conclusion: A submillimeter range accuracy was attained with a pulsed beam of about 21 ns from an FFA, at a clinical energy using relative TOF. To precisely quantify the range with a single TOF measurement, subsequent improvement in the measuring system is required.
- 26 June 2021
- Published by Wiley in Medical Physics
- Vol. 48 (9) , 5490-5500
Technical Note: Range verification of pulsed proton beams from fixed‐field alternating gradient accelerator by means of time‐of‐flight measurement of ionoacoustic waves
Purpose: Ionoacoustics is one of the promising approaches to verify the beam range in proton therapy. However, the weakness of the wave signal remains a main hindrance to its application in clinics. Here we studied the potential use of a fixed‐field alternating gradient accelerator (FFA), one of the accelerator candidates for future proton therapy. For such end, magnitude of the pressure wave and range accuracy achieved by the short‐pulsed beam of FFA were assessed, using both simulation and experimental procedure.Methods: A 100 MeV proton beam from the FFA was applied on a water phantom, through the acrylic wall. The beam range measured by the Bragg peak (BP)‐ionization chamber (BPC) was 77.6 mm, while the maximum dose at BP was estimated to be 0.35 Gy/pulse. A hydrophone was placed 20 mm downstream of the BP, and signals were amplified and stored by a digital oscilloscope, averaged, and low‐pass filtered. Time‐of‐flight (TOF) and two relative TOF values were analyzed in order to determine the beam range. Furthermore, an acoustic wave transport simulation was conducted to estimate the amplitude of the pressure waves.Results: The range calculated when using two relative TOF was 78.16 ± 0.01 and 78.14 ± 0.01 mm, respectively, both values being coherent with the range measured by the BPC (the difference was 0.5‒0.6 mm). In contrast, utilizing the direct TOF resulted in a range error of 1.8 mm. Fivefold and 50‐fold averaging were required to suppress the range variation to below 1 mm for TOF and relative TOF measures, respectively. The simulation suggested the magnitude of pressure wave at the detector exceeded 7 Pascal.Conclusion: A submillimeter range accuracy was attained with a pulsed beam of about 21 ns from an FFA, at a clinical energy using relative TOF. To precisely quantify the range with a single TOF measurement, subsequent improvement in the measuring system is required.
- Open Access
- 23 November 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-10
On-line range verification for proton beam therapy using spherical ionoacoustic waves with resonant frequency
In contrast to conventional X-ray therapy, proton beam therapy (PBT) can confine radiation doses to tumours because of the presence of the Bragg peak. However, the precision of the treatment is currently limited by the uncertainty in the beam range. Recently, a unique range verification methodology has been proposed based on simulation studies that exploit spherical ionoacoustic waves with resonant frequency (SPIREs). SPIREs are emitted from spherical gold markers in tumours initially introduced for accurate patient positioning when the proton beam is injected. These waves have a remarkable property: their amplitude is linearly correlated with the residual beam range at the marker position. Here, we present proof-of-principle experiments using short-pulsed proton beams at the clinical dose to demonstrate the feasibility of using SPIREs for beam-range verification with submillimetre accuracy. These results should substantially contribute to reducing the range uncertainty in future PBT applications.
- 23 November 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-10
Open AccessOn-line range verification for proton beam therapy using spherical ionoacoustic waves with resonant frequency
In contrast to conventional X-ray therapy, proton beam therapy (PBT) can confine radiation doses to tumours because of the presence of the Bragg peak. However, the precision of the treatment is currently limited by the uncertainty in the beam range. Recently, a unique range verification methodology has been proposed based on simulation studies that exploit spherical ionoacoustic waves with resonant frequency (SPIREs). SPIREs are emitted from spherical gold markers in tumours initially introduced for accurate patient positioning when the proton beam is injected. These waves have a remarkable property: their amplitude is linearly correlated with the residual beam range at the marker position. Here, we present proof-of-principle experiments using short-pulsed proton beams at the clinical dose to demonstrate the feasibility of using SPIREs for beam-range verification with submillimetre accuracy. These results should substantially contribute to reducing the range uncertainty in future PBT applications.
- 11 July 2020
- Published by Wiley in Medical Physics
- Vol. 47 (9) , 4644-4655
The impact of dose delivery time on biological effectiveness in proton irradiation with various biological parameters
Purpose The purpose of this study is to evaluate the sub‐lethal damage (SLD) repair effect in prolonged proton irradiation using the biophysical model with various cell‐specific parameters of (α /β )x and T 1/2 (repair half time). At present, most of the model‐based studies on protons have focused on acute radiation, neglecting the reduction in biological effectiveness due to SLD repair during the delivery of radiation. Nevertheless, the dose‐rate dependency of biological effectiveness may become more important as advanced treatment techniques, such as hypofractionation and respiratory gating, come into clinical practice, as these techniques sometimes require long treatment times. Also, while previous research using the biophysical model revealed a large repair effect with a high physical dose, the dependence of the repair effect on cell‐specific parameters has not been evaluated systematically. Methods Biological dose (relative biological effectiveness (RBE ) × physical dose) calculation with repair included was carried out using the linear energy transfer (LET)‐dependent linear‐quadratic (LQ) model combined with the theory of dual radiation action (TDRA). First, we extended the dose protraction factor in the LQ model for the arbitrary number of different LET proton irradiations delivered sequentially with arbitrary time lags, referring to the TDRA. Using the LQ model, the decrease in biological dose due to SLD repair was systematically evaluated for spread‐out Bragg peak (SOBP) irradiation in a water phantom with the possible ranges of both (α /β )x and repair parameters ((α /β )x = 1–15 Gy, T 1/2 = 0–90 min). Then, to consider more realistic irradiation conditions, clinical cases of prostate, liver, and lung tumors were examined with the cell‐specific parameters for each tumor obtained from the literature. Biological D 99% and biological dose homogeneity coefficient (HC) were calculated for the clinical target volumes (CTVs), assuming dose‐rate structures with a total irradiation time of 0–60 min. Results The differences in the cell‐specific parameters resulted in considerable variation in the repair effect. The biological dose reduction found at the center of the SOBP with 30 min of continuous irradiation varied from 1.13% to 14.4% with a T 1/2 range of 1–90 min when (α /β )x is fixed as 10 Gy. It varied from 2.3% to 6.8% with an (α /β )x range of 1–15 Gy for a fixed value of T 1/2 = 30 min. The decrease in biological D 99% per 10 min was 2.6, 1.2, and 3.0% for the prostate, liver, and lung tumor cases, respectively. The value of the biological D 99% reduction was neither in the order of (α /β )x nor prescribed dose, but both comparably contributed to the repair effect. The variation of HC was within the range of 0.5% for all cases; therefore, the dose distribution was not distorted. Conclusion The reduction in biological dose caused by the SLD repair largely depends on the cell‐specific parameters in addition to the physical dose. The parameters should be considered carefully in the evaluation of the repair effect in prolonged proton irradiation.
- 11 July 2020
- Published by Wiley in Medical Physics
- Vol. 47 (9) , 4644-4655
The impact of dose delivery time on biological effectiveness in proton irradiation with various biological parameters
Purpose The purpose of this study is to evaluate the sub‐lethal damage (SLD) repair effect in prolonged proton irradiation using the biophysical model with various cell‐specific parameters of (α /β )x and T 1/2 (repair half time). At present, most of the model‐based studies on protons have focused on acute radiation, neglecting the reduction in biological effectiveness due to SLD repair during the delivery of radiation. Nevertheless, the dose‐rate dependency of biological effectiveness may become more important as advanced treatment techniques, such as hypofractionation and respiratory gating, come into clinical practice, as these techniques sometimes require long treatment times. Also, while previous research using the biophysical model revealed a large repair effect with a high physical dose, the dependence of the repair effect on cell‐specific parameters has not been evaluated systematically. Methods Biological dose (relative biological effectiveness (RBE ) × physical dose) calculation with repair included was carried out using the linear energy transfer (LET)‐dependent linear‐quadratic (LQ) model combined with the theory of dual radiation action (TDRA). First, we extended the dose protraction factor in the LQ model for the arbitrary number of different LET proton irradiations delivered sequentially with arbitrary time lags, referring to the TDRA. Using the LQ model, the decrease in biological dose due to SLD repair was systematically evaluated for spread‐out Bragg peak (SOBP) irradiation in a water phantom with the possible ranges of both (α /β )x and repair parameters ((α /β )x = 1–15 Gy, T 1/2 = 0–90 min). Then, to consider more realistic irradiation conditions, clinical cases of prostate, liver, and lung tumors were examined with the cell‐specific parameters for each tumor obtained from the literature. Biological D 99% and biological dose homogeneity coefficient (HC) were calculated for the clinical target volumes (CTVs), assuming dose‐rate structures with a total irradiation time of 0–60 min. Results The differences in the cell‐specific parameters resulted in considerable variation in the repair effect. The biological dose reduction found at the center of the SOBP with 30 min of continuous irradiation varied from 1.13% to 14.4% with a T 1/2 range of 1–90 min when (α /β )x is fixed as 10 Gy. It varied from 2.3% to 6.8% with an (α /β )x range of 1–15 Gy for a fixed value of T 1/2 = 30 min. The decrease in biological D 99% per 10 min was 2.6, 1.2, and 3.0% for the prostate, liver, and lung tumor cases, respectively. The value of the biological D 99% reduction was neither in the order of (α /β )x nor prescribed dose, but both comparably contributed to the repair effect. The variation of HC was within the range of 0.5% for all cases; therefore, the dose distribution was not distorted. Conclusion The reduction in biological dose caused by the SLD repair largely depends on the cell‐specific parameters in addition to the physical dose. The parameters should be considered carefully in the evaluation of the repair effect in prolonged proton irradiation.
- Open Access
- 9 March 2020
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 21 (4) , 42-50
Difference in LET‐based biological doses between IMPT optimization techniques: Robust and PTV‐based optimizations
Purpose: While a large amount of experimental data suggest that the proton relative biological effectiveness (RBE) varies with both physical and biological parameters, current commercial treatment planning systems (TPS) use the constant RBE instead of variable RBE models, neglecting the dependence of RBE on the linear energy transfer (LET). To conduct as accurate a clinical evaluation as possible in this circumstance, it is desirable that the dosimetric parameters derived by TPS () are close to the “true” values derived with the variable RBE models (). As such, in this study, the closeness of to was compared between planning target volume (PTV)‐based and robust plans.Methods: Intensity‐modulated proton therapy (IMPT) treatment plans for two Radiation Therapy Oncology Group (RTOG) phantom cases and four nasopharyngeal cases were created using the PTV‐based and robust optimizations, under the assumption of a constant RBE of 1.1. First, the physical dose and dose‐averaged LET (LETd) distributions were obtained using the analytical calculation method, based on the pencil beam algorithm. Next, was calculated using three different RBE models. The deviation of from was evaluated with D99 and Dmax, which have been used as the evaluation indices for clinical target volume (CTV) and organs at risk (OARs), respectively. The influence of the distance between the OAR and CTV on the results was also investigated. As a measure of distance, the closest distance and the overlapped volume histogram were used for the RTOG phantom and nasopharyngeal cases, respectively.Results: As for the OAR, the deviations of from were always smaller in robust plans than in PTV‐based plans in all RBE models. The deviation would tend to increase as the OAR was located closer to the CTV in both optimization techniques. As for the CTV, the deviations of from were comparable between the two optimization techniques, regardless of the distance between the CTV and the OAR.Conclusion: Robust optimization was found to be more favorable than PTV‐based optimization in that the results presented by TPS were closer to the “true” values and that the clinical evaluation based on TPS was more reliable.
- 9 March 2020
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 21 (4) , 42-50
Open AccessDifference in LET‐based biological doses between IMPT optimization techniques: Robust and PTV‐based optimizations
Purpose: While a large amount of experimental data suggest that the proton relative biological effectiveness (RBE) varies with both physical and biological parameters, current commercial treatment planning systems (TPS) use the constant RBE instead of variable RBE models, neglecting the dependence of RBE on the linear energy transfer (LET). To conduct as accurate a clinical evaluation as possible in this circumstance, it is desirable that the dosimetric parameters derived by TPS () are close to the “true” values derived with the variable RBE models (). As such, in this study, the closeness of to was compared between planning target volume (PTV)‐based and robust plans.Methods: Intensity‐modulated proton therapy (IMPT) treatment plans for two Radiation Therapy Oncology Group (RTOG) phantom cases and four nasopharyngeal cases were created using the PTV‐based and robust optimizations, under the assumption of a constant RBE of 1.1. First, the physical dose and dose‐averaged LET (LETd) distributions were obtained using the analytical calculation method, based on the pencil beam algorithm. Next, was calculated using three different RBE models. The deviation of from was evaluated with D99 and Dmax, which have been used as the evaluation indices for clinical target volume (CTV) and organs at risk (OARs), respectively. The influence of the distance between the OAR and CTV on the results was also investigated. As a measure of distance, the closest distance and the overlapped volume histogram were used for the RTOG phantom and nasopharyngeal cases, respectively.Results: As for the OAR, the deviations of from were always smaller in robust plans than in PTV‐based plans in all RBE models. The deviation would tend to increase as the OAR was located closer to the CTV in both optimization techniques. As for the CTV, the deviations of from were comparable between the two optimization techniques, regardless of the distance between the CTV and the OAR.Conclusion: Robust optimization was found to be more favorable than PTV‐based optimization in that the results presented by TPS were closer to the “true” values and that the clinical evaluation based on TPS was more reliable.
- Open Access
- 24 June 2019
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 20 (7) , 48-57
Physical and biological impacts of collimator‐scattered protons in spot‐scanning proton therapy
To improve the penumbra of low‐energy beams used in spot‐scanning proton therapy, various collimation systems have been proposed and used in clinics. In this paper, focused on patient‐specific brass collimators, the collimator‐scattered protons' physical and biological effects were investigated. The Geant4 Monte Carlo code was used to model the collimators mounted on the scanning nozzle of the Hokkaido University Hospital. A systematic survey was performed in water phantom with various‐sized rectangular targets; range (5–20 cm), spread‐out Bragg peak (SOBP) (5–10 cm), and field size (2 × 2–16 × 16 cm2). It revealed that both the range and SOBP dependences of the physical dose increase had similar trends to passive scattering methods, that is, it increased largely with the range and slightly with the SOBP. The physical impact was maximized at the surface (3%–22% for the tested geometries) and decreased with depth. In contrast, the field size (FS) dependence differed from that observed in passive scattering: the increase was high for both small and large FSs. This may be attributed to the different phase‐space shapes at the target boundary between the two dose delivery methods. Next, the biological impact was estimated based on the increase in dose‐averaged linear energy transfer (LETd) and relative biological effectiveness (RBE). The LETd of the collimator‐scattered protons were several keV/μm higher than that of unscattered ones; however, since this large increase was observed only at the positions receiving a small scattered dose, the overall LETd increase was negligible. As a consequence, the RBE increase did not exceed 0.05. Finally, the effects on patient geometries were estimated by testing two patient plans, and a negligible RBE increase (0.9% at most in the critical organs at surface) was observed in both cases. Therefore, the impact of collimator‐scattered protons is almost entirely attributed to the physical dose increase, while the RBE increase is negligible.
- 24 June 2019
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 20 (7) , 48-57
Open AccessPhysical and biological impacts of collimator‐scattered protons in spot‐scanning proton therapy
To improve the penumbra of low‐energy beams used in spot‐scanning proton therapy, various collimation systems have been proposed and used in clinics. In this paper, focused on patient‐specific brass collimators, the collimator‐scattered protons' physical and biological effects were investigated. The Geant4 Monte Carlo code was used to model the collimators mounted on the scanning nozzle of the Hokkaido University Hospital. A systematic survey was performed in water phantom with various‐sized rectangular targets; range (5–20 cm), spread‐out Bragg peak (SOBP) (5–10 cm), and field size (2 × 2–16 × 16 cm2). It revealed that both the range and SOBP dependences of the physical dose increase had similar trends to passive scattering methods, that is, it increased largely with the range and slightly with the SOBP. The physical impact was maximized at the surface (3%–22% for the tested geometries) and decreased with depth. In contrast, the field size (FS) dependence differed from that observed in passive scattering: the increase was high for both small and large FSs. This may be attributed to the different phase‐space shapes at the target boundary between the two dose delivery methods. Next, the biological impact was estimated based on the increase in dose‐averaged linear energy transfer (LETd) and relative biological effectiveness (RBE). The LETd of the collimator‐scattered protons were several keV/μm higher than that of unscattered ones; however, since this large increase was observed only at the positions receiving a small scattered dose, the overall LETd increase was negligible. As a consequence, the RBE increase did not exceed 0.05. Finally, the effects on patient geometries were estimated by testing two patient plans, and a negligible RBE increase (0.9% at most in the critical organs at surface) was observed in both cases. Therefore, the impact of collimator‐scattered protons is almost entirely attributed to the physical dose increase, while the RBE increase is negligible.
- Open Access
- 8 March 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 4011
A novel range-verification method using ionoacoustic wave generated from spherical gold markers for particle-beam therapy: a simulation study
This study proposes a novel alternative range-verification method for proton beam with acoustic waves generated from spherical metal markers. When proton beam is incident on metal markers, most of the resulting pressure waves are confined in the markers because of the large difference in acoustic impedance between the metal and tissue. However, acoustic waves with frequency equal to marker’s resonant frequency escape this confinement; the marker briefly acts as an acoustic transmitter. Herein, this phenomenon is exploited to measure the range of the proton beam. We test the proposed strategy in 3-D simulations, combining the dose calculations with modelling of acoustic-wave propagation. A spherical gold marker of 2.0 mm diameter was placed in water with a 60 MeV proton beam incident on it. We investigated the dependence of pressure waves on the width of beam pulse and marker position. At short beam pulse, specific high-frequency acoustic waves of 1.62 MHz originating from the marker were observed in wave simulations, whose amplitude correlated with the distance between the marker and Bragg peak. Results indicate that the Bragg peak position can be estimated by measuring the acoustic wave amplitudes from the marker, using a single detector properly designed for the resonance frequency.
- 8 March 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 4011
Open AccessA novel range-verification method using ionoacoustic wave generated from spherical gold markers for particle-beam therapy: a simulation study
This study proposes a novel alternative range-verification method for proton beam with acoustic waves generated from spherical metal markers. When proton beam is incident on metal markers, most of the resulting pressure waves are confined in the markers because of the large difference in acoustic impedance between the metal and tissue. However, acoustic waves with frequency equal to marker’s resonant frequency escape this confinement; the marker briefly acts as an acoustic transmitter. Herein, this phenomenon is exploited to measure the range of the proton beam. We test the proposed strategy in 3-D simulations, combining the dose calculations with modelling of acoustic-wave propagation. A spherical gold marker of 2.0 mm diameter was placed in water with a 60 MeV proton beam incident on it. We investigated the dependence of pressure waves on the width of beam pulse and marker position. At short beam pulse, specific high-frequency acoustic waves of 1.62 MHz originating from the marker were observed in wave simulations, whose amplitude correlated with the distance between the marker and Bragg peak. Results indicate that the Bragg peak position can be estimated by measuring the acoustic wave amplitudes from the marker, using a single detector properly designed for the resonance frequency.
- Open Access
- 5 January 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (1) , 48
A Literature Review of Proton Beam Therapy for Prostate Cancer in Japan
Aim: Patients of proton beam therapy (PBT) for prostate cancer had been continuously growing in number due to its promising characteristics of high dose distribution in the tumor target and a sharp distal fall-off. Considering the large number of proton beam facilities in Japan, the further increase of patients undergoing this treatment is due to the emendations by Japanese National Health Insurance (NHI) and the development of medical equipment and technology, it is necessary to know what kind of research and advancements has been done on proton therapy for prostate cancer in the country. For these reasons, this literature review was conducted. The aim of this review is to identify and discuss research studies of proton beam therapy for prostate cancer in Japan. These include observational, interventional, and secondary data analysis of published articles. Method: A literature review on published works related to proton beam therapy for prostate cancer in Japan was conducted using articles that were gathered in the PubMed database of June 2018. We went through abstracts and manuscripts written in English with the keywords ‘proton beam therapy’, ‘prostate cancer’, and ‘Japan’. Results: A total of 23 articles were included. Fourteen articles were observational studies, most of which focused on the adverse effects of Proton Beam Therapy (PBT). Seven articles were interventional studies related on treatment planning, equipment parts, as well as target positioning. Two were secondary data analysis. The included studies were published in 13 different journals by different institutions using various equipment. Conclusion: Despite the favorable results of proton beam therapy, future research should include more patients and longer follow-up schedules to clarify the definitive role of PBT, yet, up to recent retrospective studies, included in this paper, concluded that PBT can be a suitable treatment option for localized prostate cancer. In addition, interventional studies were conducted by several institutions to further embellish proton therapy.
- 5 January 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (1) , 48
Open AccessA Literature Review of Proton Beam Therapy for Prostate Cancer in Japan
Aim: Patients of proton beam therapy (PBT) for prostate cancer had been continuously growing in number due to its promising characteristics of high dose distribution in the tumor target and a sharp distal fall-off. Considering the large number of proton beam facilities in Japan, the further increase of patients undergoing this treatment is due to the emendations by Japanese National Health Insurance (NHI) and the development of medical equipment and technology, it is necessary to know what kind of research and advancements has been done on proton therapy for prostate cancer in the country. For these reasons, this literature review was conducted. The aim of this review is to identify and discuss research studies of proton beam therapy for prostate cancer in Japan. These include observational, interventional, and secondary data analysis of published articles. Method: A literature review on published works related to proton beam therapy for prostate cancer in Japan was conducted using articles that were gathered in the PubMed database of June 2018. We went through abstracts and manuscripts written in English with the keywords ‘proton beam therapy’, ‘prostate cancer’, and ‘Japan’. Results: A total of 23 articles were included. Fourteen articles were observational studies, most of which focused on the adverse effects of Proton Beam Therapy (PBT). Seven articles were interventional studies related on treatment planning, equipment parts, as well as target positioning. Two were secondary data analysis. The included studies were published in 13 different journals by different institutions using various equipment. Conclusion: Despite the favorable results of proton beam therapy, future research should include more patients and longer follow-up schedules to clarify the definitive role of PBT, yet, up to recent retrospective studies, included in this paper, concluded that PBT can be a suitable treatment option for localized prostate cancer. In addition, interventional studies were conducted by several institutions to further embellish proton therapy.